Hôpital Paul-Brousse

Running trials

• Not yet recruiting

  A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma

  2025-522563-15-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

  NCT07439939· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study

  2024-517766-41-00· Phase 2· Association Gercor· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

  NCT06254248· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

  NCT07044453· Phase 2/3· University Hospital, Rouen· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma

  2024-516233-12-00· Phase 1· Asociacion Grupo Tratamiento De Tumores Digestivos· Source

• Not yet recruiting

  PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

  NCT07028424· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Not yet recruiting

  Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial

  NCT06263816· Phase 3· University Hospital, Tours· Source

• Not yet recruiting

  SIRT and Peri-immunotherapy : a New Concept

  NCT06971237· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Safety of HRX215 in Patients After Minor and Major Liver Resection

  NCT06638502· Phase 1/2· HepaRegeniX GmbH· Source

• Active, not recruiting

  Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC

  2024-516063-89-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals

  NCT06694428· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· Phase 3· AstraZeneca· Source

• Recruiting

  Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

  2024-515362-13-00· Phase 2/3· Centre Hospitalier Regional Et Universitaire De Brest· Source

• Active, not recruiting

  Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and immunotherapy ( Pembrolizumab)

  NCT04262687· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· UNICANCER· Source

• Recruiting

  First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

  NCT06253611· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Active, not recruiting

  BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

  NCT05911633· Terumo Europe N.V.· Source

• Recruiting

  ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

  NCT05787197· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Recruiting

  Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients

  NCT05850130· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Active, not recruiting

  TheraSphere With Durvalumab and Tremelimumab for HCC

  NCT05063565· Phase 2· Boston Scientific Corporation· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Not yet recruiting

  Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma

  NCT05971628· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

• Active, not recruiting

  Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation

  NCT05701228· University Hospital, Bordeaux· Source

• Recruiting

  Hepatic and Systemic Hemodynamic Modeling During Liver Surgery

  NCT05339984· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  NCT05528952· Phase 2· Centre Hospitalier Universitaire de Besancon· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

  NCT05050136· Phase 2· Mirum Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Recruiting

  Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

  NCT04613921· European Foundation for Study of Chronic Liver Failure· Source

• Recruiting

  Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  NCT04570943· Phase 2· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Active, not recruiting

  Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma

  NCT04791735· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

  NCT04770896· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

  NCT03806309· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Active, not recruiting

  Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

  NCT04421963· Phase 3· AstraZeneca· Source

• Recruiting

  National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

  NCT04166266· ANRS, Emerging Infectious Diseases· Source

• Active, not recruiting

  Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

  NCT04070443· Phase 2· Centre Leon Berard· Source

• Recruiting

  Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

  NCT02885753· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Chronic Myeloid Leukemia (CML) Real-Life Database

  NCT05963061· University Hospital, Clermont-Ferrand· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

  NCT00005584· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer15 recruiting
• Liver and biliary tract cancer10 recruiting
• Colorectal cancer4 recruiting
• Liver cirrhosis4 recruiting
• High blood pressure3 recruiting
• Gastric and oesophageal cancer2 recruiting
• Primary biliary cholangitis2 recruiting
• Childhood cancers1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Cytomegalovirus infection1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hepatitis B1 recruiting
• Metastatic breast cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Completed

  Effects of Platelet Mimicking Nanoparticles in Patients With Cirrhosis

  NCT06050993· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma (Morpheus-Neo HCC)

  2022-502840-11-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

  NCT05525520· Phase 2· Escient Pharmaceuticals, Inc· Source

• Completed

  A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab and Bevacizumab

  2023-503229-21-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Bayer· Source

• Completed

  Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma

  NCT04246177· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)

  NCT04483726· University Hospital, Montpellier· Source

• Completed

  A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

  NCT04039607· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

  NCT03841305· Phase 2· University Hospital, Montpellier· Source

• Completed

  Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality

  NCT03702920· Phase 3· Instituto Grifols S.A.· Source

• Completed

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Boston Scientific Corporation· Source

• Completed

  "Early TIPS" Versus Glue Obliteration to Prevent Rebleeding From Gastric Varices

  NCT03705078· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation

  2023-508726-10-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

  NCT02676349· Phase 2· Institut de Cancérologie de Lorraine· Source

• Completed

  Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

  NCT02738125· AbbVie· Source